Latest News

STAT Plus: Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug

Shares of Biogen fell Thursday after a federal court judge ruled in favor of generic drug maker Mylan in a patent case involving the biotech’s top-selling multiple sclerosis drug, Tecfidera.

The U.S. District Court in West Virginia declared invalid Biogen’s so-called “514” patent protecting Tecfidera from generic competition. The ruling gives Mylan the right to launch its own version of Tecfidera within days, although Biogen said Thursday that an appeal will be filed.

Continue to STAT Plus to read the full story…

Source link

Related posts

Medical News Today: How can you tell when a toddler is dehydrated?


$2.16 Bn Bariatric Surgery Devices Market – Global Forecast to 2023 –


STAT Plus: What we learned about the business of telemedicine from Amwell and GoodRx’s IPO filings


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World